Negative dry AMD results
Emixustat fails to slow geographic atrophy in 24-month trial
Howard Larkin
Published: Wednesday, March 1, 2017
Frank G Holz MD
Unlike most drugs for AMD and other eye diseases, emixustat hydrochloride is taken orally rather than topically or intravitreallyThe primary efficacy endpoint was the mean rate of change from baseline in total GA area in the study eye as imaged by fundus autofluorescence. Patients were examined at baseline, months 1, 2, 3, 6, 9, 12, 15, 18, and 24, with the study exit visit 30 days after the last dose. No statistically significant differences among the three treatment or placebo groups were observed at 6, 12, 18 or 24 months. Rates of loss of visual acuity were also similar for the four groups, with mean losses by group ranging from about five to eight ETDRS letters at the exit visit. “The data from this study are very important to further elucidate the natural history of GA,” Dr Holz said. Frank G Holz: frank.holz@ukbonn.de
Tags: AMD, Emixustat hydrochloride, geographic atrophy
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Best of ESCRS Winter Meeting 2024
Following the New Generation
EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.
Refocus on Multifocals
Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.
Common Myths in Presbyopia Correction
Patient education key to satisfaction with refractive IOLs.
Reversible Multifocality
Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.
Managing a Cataract Surgery Refractive Miss
Weighing the pros and cons of options for intraocular intervention.
Unleashing OCT’s Full Potential
Performance of newest tool for corneal evaluation meets or beats older standard technologies.